Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
|Slideshows|October 23, 2019
When Eating Disorders and Psychosis Co-Exist: 6 Take Home Points
Author(s)Mary V. Seeman, MDCM, DSc
The body image disturbance at the heart of anorexia nervosa is a false perception akin to the perceptual disorders found in schizophrenia.
Advertisement
Advertisement
Related to this article
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Male athletes with anorexia often go unnoticed as “discipline”; learn red flags, sport-specific risks, health consequences, and treatment steps for earlier diagnosis.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
A remitted patient with ARFID faces panic after a crash, showing why recovery includes somatic fear, not just eating behavior.
Advertisement
Advertisement
Trending on Psychiatric Times
1
How Best to Manage Treatment-Resistant Depression
2
Anorexia Nervosa in Male Athletes: Clinical Recognition and Diagnostic Challenges
3
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
4
Can Durable Response to Psilocybin Reshape Treatment-Resistant Depression Care?
5